<DOC>
	<DOC>NCT00563225</DOC>
	<brief_summary>A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus</brief_summary>
	<brief_title>20 Week Bridging Study in Type II DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 Diabetes Mellitus diagnosed at least 3 years ago Treated concomitantly with insulin once a day and SU over at least 3 months prior to study entry Treated with OHA monotherapy over at least 1 year HbA1c greater than or equal to 7.5% and less than or equal to 12.0%, at visit 1 (screening visit) BMI &lt; 40 kg/m2 No history of ketonemia Women of childbearing potential using the medically approved contraceptive method Ability and willingness to perform blood glucose monitoring using a blood glucose meter as per the requirement of protocol The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>